<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04915729</url>
  </required_header>
  <id_info>
    <org_study_id>1123-0040</org_study_id>
    <nct_id>NCT04915729</nct_id>
  </id_info>
  <brief_title>A Study in Chinese Patients to Compare How Tenecteplase and Alteplase Given After a Stroke Improve Recovering of Physical Activity</brief_title>
  <official_title>A Phase III Multi-centre, Prospective, Randomised, Open Label, Blinded Endpoint (PROBE), Active-controlled Parallel Group Trial to Assess Efficacy and Safety of Tenecteplase Versus Alteplase in Chinese Patients With Acute Ischaemic Stroke Within 4.5 Hours After Stroke Onset</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to Chinese adults who had an ischaemic stroke, which means that blood&#xD;
      vessels in the brain are blocked. To resolve blood clots, people in the study get either&#xD;
      tenecteplase or alteplase within 4 hours and 30 minutes after stroke. The purpose of this&#xD;
      study is to compare how tenecteplase and alteplase improve peoples' recovering of physical&#xD;
      activity. Alteplase is standard of care. Tenecteplase is a modified variant of alteplase that&#xD;
      is easier to administer and is approved to treat heart attack. This study is to find out&#xD;
      whether tenecteplase is as good as alteplase in people with ischaemic stroke.&#xD;
&#xD;
      Participants are equally put into 2 treatment groups by chance. Participants in one group get&#xD;
      tenecteplase as a single injection into a vein. Participants in the other group get alteplase&#xD;
      as an injection into a vein (10% of the dose) and the remainder as an infusion over 1 hour.&#xD;
&#xD;
      Participants are in the study for about 3 months. They are in the hospital for the first week&#xD;
      after treatment. Then they visit the study site 1 and 3 months after treatment. At these&#xD;
      visits, peoples' ability to independently carry out daily activities is assessed. Scores for&#xD;
      physical activity are compared between both treatment groups. The doctors also regularly&#xD;
      check the general health of the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 22, 2021</start_date>
  <completion_date type="Anticipated">May 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">May 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modified Rankin Scale (mRS) score of 0 or 1</measure>
    <time_frame>up to 90 days</time_frame>
    <description>Modified Rankin Scale (mRS) is a standardized measure that describes the extent of disability after a stroke. The mRS is a single item scale. It increases from 0 (no symptoms at all) to 6 (death).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major neurological improvement (National Institutes of Health Stroke Scale (NIHSS) score of 0 or improvement of at least 4 points compared with baseline)</measure>
    <time_frame>up to 24 hours</time_frame>
    <description>National Institutes of Health Stroke Scale (NIHSS) is a 11-item neurologic examination stroke scale used to evaluate the effect of acute cerebral infarction on the levels of consciousness, language, neglect, visual-field loss, extraocular movement, motor strength, ataxia, dysarthria, and sensory loss. A trained observer rates the patent's ability to answer questions and perform activities. Ratings for each item are scored with 3 to 6 grades with 0 as normal, and there is an allowance for untestable items.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) score of 0-2</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline of National Institutes of Health Stroke Scale (NIHSS) score</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distribution of Modified Rankin Scale (mRS)</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Barthel Index score ≥95</measure>
    <time_frame>up to 90 days</time_frame>
    <description>The Barthel Index is an ordinal scale used to measure performance in activities of daily living (ADL). The Barthel Index consists of 10 items. The total score of the Barthel Index ranges from 0 to 100, and higher scores indicate better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic Intracerebral Haemorrhage (sICH) per European Cooperative Acute Stroke Study (ECASS) Ⅲ definition</measure>
    <time_frame>up to 36 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modified Rankin Scale (mRS) score of 5 or 6</measure>
    <time_frame>up to 90 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">800</enrollment>
  <condition>Stroke</condition>
  <arm_group>
    <arm_group_label>tenecteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>alteplase</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Active control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tenecteplase</intervention_name>
    <description>tenecteplase</description>
    <arm_group_label>tenecteplase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alteplase</intervention_name>
    <description>alteplase</description>
    <arm_group_label>alteplase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years old&#xD;
&#xD;
          -  Diagnosis of ischaemic stroke with a measurable neurological deficit on National&#xD;
             Institutes of Health Stroke Scale (NIHSS) (0&lt; NIHSS ≤25); if NIHSS &lt;4, patients have&#xD;
             to be with at least a measurable deficit on motor power (upper or lower limbs ≥1)&#xD;
&#xD;
          -  Stroke symptoms should have been present for at least 30 minutes (min) without&#xD;
             significant improvement prior to randomisation&#xD;
&#xD;
          -  Thrombolytic therapy can be initiated within 4.5 Hour(s) (h) of Acute ischaemic stroke&#xD;
             (AIS) onset&#xD;
&#xD;
          -  Patients with premorbid modified Rankin Scale (mRS) 0 or 1&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with good clinical practice&#xD;
             (GCP) and local legislation prior to trial admission&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of intracranial haemorrhage on the Computed tomography (CT) scan or symptoms&#xD;
             suggestive of subarachnoid haemorrhage, even if the CT scan is normal&#xD;
&#xD;
          -  Patients who must or are expected to continue the intake of restricted medications or&#xD;
             any drug considered likely to interfere with the safe conduct of the trial&#xD;
&#xD;
          -  Acute bleeding diathesis, including but not limited to&#xD;
&#xD;
               -  Known genetic predisposition to bleeding or significant bleeding disorder at&#xD;
                  present or within the past 6 Month(s) (m)&#xD;
&#xD;
               -  Administration of heparin within the previous 48 h and activated partial&#xD;
                  thromboplastin time (aPTT) exceeding the upper limit of normal for laboratory&#xD;
                  measurement&#xD;
&#xD;
               -  Current use of vitamin K based oral anticoagulants (e.g. warfarin) and a&#xD;
                  prolonged prothrombin time (International normalised Ratio (INR) &gt; 1.7 or&#xD;
                  Prothrombin time (PT)&gt;15 seconds (s)) or current use of novel oral anticoagulants&#xD;
                  (i.e. dabigitran, rivaroxiban, or apixiban) with prolongation of activated&#xD;
                  partial thromboplastin time (aPTT) and/or PT above the upper limit of the local&#xD;
                  laboratory reference range&#xD;
&#xD;
               -  Platelet count of below 100,000/mm3 at screening&#xD;
&#xD;
               -  Any history of central nervous system damage (i.e. neoplasm, aneurysm,&#xD;
                  intracranial or spinal surgery)&#xD;
&#xD;
               -  Recent traumatic external heart massage, obstetrical delivery, or recent puncture&#xD;
                  of a non-compressive blood-vessel (e.g. subclavian or jugular vein puncture) ,&#xD;
                  within the past 10 days&#xD;
&#xD;
               -  Known history of suspected intracranial haemorrhage or suspected subarachnoid&#xD;
                  haemorrhage from aneurysm&#xD;
&#xD;
               -  Neoplasm with increased haemorrhagic risk&#xD;
&#xD;
               -  Documented ulcerative gastrointestinal disease during the last 3 m, oesophageal&#xD;
                  varices, arterial aneurysm, or arterial/venous malformations&#xD;
&#xD;
               -  Any known disorder associated with a significant increased risk of bleeding&#xD;
&#xD;
          -  Bacterial endocarditis or pericarditis at screening&#xD;
&#xD;
          -  Acute pancreatitis at screening&#xD;
&#xD;
          -  Significant trauma or major surgery (according to the investigator's assessment) in&#xD;
             the past 3 m&#xD;
&#xD;
          -  Imaging demonstrates multi-lobar infarction (hypodensity &gt;1/3 cerebral hemisphere)&#xD;
&#xD;
          -  Severe uncontrolled arterial hypertension, e.g. systolic blood pressure (BP) &gt;185 mmHg&#xD;
             or diastolic BP &gt;110 mmHg Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Chao-Yang Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wenli Hu</last_name>
      <phone>13552983366</phone>
      <email>huwenli11230040@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tiantan Hospital affiliated to Cap Med University</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yongjun Wang</last_name>
      <phone>13911172565</phone>
      <email>metalysewyj@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jiawei Wang</last_name>
      <phone>13651110820</phone>
      <email>wangjwcq@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yi Yang</last_name>
      <phone>8613756661217</phone>
      <email>doctoryangyi@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The third xiangya hospital of Central South University</name>
      <address>
        <city>Changsha</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ruxu Zhang</last_name>
      <phone>+8618975172668</phone>
      <email>zhangruxu@vip.163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shengli Oilfield central hospital</name>
      <address>
        <city>Dongying</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yingchun Liu</last_name>
      <phone>18678699722</phone>
      <email>18678699722@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Third Affiliated Hospital of Guangzhou Medical University</name>
      <address>
        <city>Guangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yanling Liang</last_name>
      <phone>13828756497</phone>
      <email>elaine.liang@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Guizhou Medical University</name>
      <address>
        <city>Guiyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lan Chu</last_name>
      <phone>13885181667</phone>
      <email>chulan8999@yeah.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Affiliated Hospital of Hangzhou Normal University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaodong Lu</last_name>
      <phone>18806815058</phone>
      <email>xdlu668@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Second Affiliated Hospital of Nanjing Medical University</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Wu</last_name>
      <phone>18951762859</phone>
      <email>wujin@njmu.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang Province People's Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yu Geng</last_name>
      <phone>13588011488</phone>
      <email>gengy2004@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhejiang University School of Medicine SIR RUN RUN SHAW Hospital</name>
      <address>
        <city>Hangzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xingyue Hu</last_name>
      <phone>13805736386</phone>
      <email>huxingyue2003@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Center Hospital of Jinan</name>
      <address>
        <city>Jinan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohong Li</last_name>
      <phone>13370582096</phone>
      <email>lxh5231@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Taizhou Hospital of Zhejiang Province</name>
      <address>
        <city>Linhai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaofa Ke</last_name>
      <phone>13566862208</phone>
      <email>ksf667@sohu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Nanning</name>
      <address>
        <city>Nanning</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xianfeng Li</last_name>
      <phone>+8613517816889</phone>
      <email>lxianf@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First People's Hospital of Nantong</name>
      <address>
        <city>Nantong</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiangyang Zhu</last_name>
      <phone>13962978278</phone>
      <email>zhuxxyy@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ruian People's Hospital</name>
      <address>
        <city>Ruian</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shunkai Zhang</last_name>
      <phone>+8613806807851</phone>
      <email>zsk7851@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai East Hospital, Tongji University China</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gang Li</last_name>
      <phone>13621691786</phone>
      <email>ligang@tongji.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Seventh People's Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wang</last_name>
      <phone>13301991888</phone>
      <email>13816566556@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tianjin Medical University General Hospital</name>
      <address>
        <city>Tianjin</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fudong Shi</last_name>
      <phone>022-60814603</phone>
      <email>tjmughn@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Union Hospital Tongji Medical College Huazhong University of Science and Technology</name>
      <address>
        <city>Wuhan</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bo Hu</last_name>
      <phone>13707114863</phone>
      <email>hubo@mail.hust.edu.cn</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wuxi People's Hospital</name>
      <address>
        <city>Wuxi</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Feng Wang</last_name>
      <phone>+8615961896462</phone>
      <email>wangfeng717798@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Xianyang Hospital of Yan'an University</name>
      <address>
        <city>Xianyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Weiwei Wang</last_name>
      <phone>15929201829</phone>
      <email>5935328@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital, Xuzhou Medical college</name>
      <address>
        <city>Xuzhou</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deqin Geng</last_name>
      <phone>+8613003509017</phone>
      <email>gengdeqin@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yiyang Central Hospital</name>
      <address>
        <city>Yiyang</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianhua Cao</last_name>
      <phone>13370582096</phone>
      <email>cjh66187@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 4, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
    <mesh_term>Tenecteplase</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

